The European Medicines Agency’s Updated Guidelines for JAK Inhibitors in Rheumatoid Arthritis – A Cause for Concern? Spherix Investigates
Surveyed EU5 rheumatologists indicate newfound shaky perceptions of the JAK class, though whether overall brand share and use will be affected is still in question EXTON, Pa., December 2, 2022 /PRNewswire/ — On October 28, 2022, the European Medicines Agency’s (EMA) safety committee (PRAC) announced recommendations to minimize the risk of serious side effects when using […]
Further Education Needed for the Proper Diagnosis of Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis in the EU5, Spherix Global Insights Reports
Referrals from primary care physicians to rheumatologists are being delayed due to several factors EXTON, Pa., November 10, 2022 /PRNewswire/ – Rheumatologists in the EU5 (France, Germany, Italy, Spain, and the United Kingdom) recognize a disconnect in the diagnosis and referral process for ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA) patients. The lack of […]
European Lupus Market Coverage Highlights Pipeline Perceptions and Country Differences in Patient Management, Spherix Reports
Expanded systemic lupus erythematosus (SLE) research in Europe reveals UK physicians perceive a higher unmet need and difficulty in treating SLE patients compared to other EU markets, though prescribe approved advanced therapy options less often EXTON, Pa., October 26, 2022 /PRNewswire/ — Rheumatologists have long struggled to effectively treat patients with systemic lupus erythematosus (SLE) […]
The Psoriatic Arthritis Landscape Continues to Evolve as New Launches Alter Dynamics in Both US and EU Markets, Spherix Reports
IL-23 inhibitors and AbbVie’s Rinvoq are projected to have the largest growth in the coming months EXTON, Pa., October 13, 2022 /PRNewswire/ – TNF inhibitors continue to be the mainstay for treating psoriatic arthritis (PsA), largely driven by the gold standards, etanercept and adalimumab. However, the recent entrance of IL-23 inhibitors (Janssen’s Tremfya and AbbVie’s […]
Economic Burden Forces Shift in Specialty Physicians’ Treatment Decisions and Relationship with Pharma, According to New Spherix Report
The inflationary economy and lasting effects of COVID-19 have caused staff and product shortages, a rise in labor costs, and increased patient sensitivity to medication costs EXTON, Pa., September 12, 2022 /PRNewswire/ — Over the past year, many countries have reported multi-decade highs in inflation, with the United States recording its highest inflation rate in […]
Implications of Expanded Biosimilar Use in the United States’ Dermatology, Gastroenterology, and Rheumatology Markets Highlighted in New Spherix Study
232 US specialists provided feedback on their use and perceptions of biosimilar agents and their impact on the total treatment landscape EXTON, Pa., July 7, 2022 /PRNewswire/ – Biosimilars are biopharmaceutical products that are nearly identical copies of drugs that have previously been licensed (reference products), with no clinically meaningful efficacy and safety differences from […]
Spherix Research Reveals Rheumatologists Taking the Lead Over Nephrologists in Both BENLYSTA (GlaxoSmithKline) and LUPKYNIS (Aurinia) Patient Initiations in Lupus Nephritis
Nephrologists and rheumatologists are approaching the new products from very different perspectives EXTON, Pa., June 17, 2022 /PRNewswire/ —With the approvals of GlaxoSmithKline’s Benlysta in lupus nephritis (LN) at the end of 2020 and Aurinia’s Lupkynis at the beginning of 2021, practitioners now have valuable new treatment options to battle this complex condition. Spherix has been […]
Novartis’ Cosentyx and Eli Lilly’s Taltz Remain Leaders in US and EU5 Psoriatic Arthritis Switching Market, but Janssen’s Tremfya and AbbVie’s Skyrizi Are Picking Up Steam, Spherix Reports
Rheumatologists are more likely than PsA-treating dermatologists to cycle TNFs prior to introducing an alternative mechanism of action agent EXTON, Pa., June 14, 2022 / PRNewswire/ — Spherix Global Insights, a leading market intelligence firm specializing in immunology-based research and insights, recently published several large-scale patient audits focused on psoriatic arthritis (PsA) patients recently switched […]
Spherix Global Insights Announces Fielding of New Research Geared Towards Fellows and Residents in Immunology, Neurology, Nephrology, and Ophthalmology
The project is designed to explore to what degree the next generation of specialists are prepared to enter clinical practice and what baseline opinions will they be bringing as they move from a training environment into real world patient management EXTON, Pa., June 7, 2022 /PRNewswire/ — Fellows will be the next generation of practitioners. […]
RA Patients in Great Need of New Treatment Options
Almost half, 49 percent, of rheumatologists, decreased prescriptions of Xeljanz over the past three months, according to Spherix Global Insights’ report for the first quarter. The decline in the prescription of Rinvoq and Olumiant was not as big during the period – just under 25 percent of rheumatologists reduced their use of these JAK inhibitors…
